Phase II trial of vorinostat in advanced melanoma von Haas, N. B., Quirt, I., Hotte, S., McWhirter, E., Polintan, R., Litwin, S., Adams, P. D., McBryan, T., Wang, L., Martin, L. P., vonMehren, M., Alpaugh, R. K., Zweibel, J., Oza, A.

Volltext

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Ma... von Mackay, H.J, Buckanovich, R.J, Hirte, H, Correa, R, Hoskins, P, Biagi, J, Martin, L.P, Fleming, G.F, Morgan, R, Wang, L, Polintan, R, Oza, A.M

Volltext

Phase II study of vorinostat in patients with advanced melanoma von Haas, N. B., McWhirter, E., Hogg, D., Martin, L. P., Polintan, R., Litwin, S., Wang, L., Alpaugh, R. K., Zwiebel, J. A., Oza, A. M.

Volltext

A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium von Townsley, C., Hirte, H., Hoskins, P., Buckanovich, R., Mackay, H., Welch, S., Wang, L., Polintan, R., Chen, A., Oza, A. M.

Volltext

The effect of calcination rate on the structure of mesoporous bioactive glasses von Rahman, Saidur, Mendonca, Andrew, Alhalawani, Adel, Polintan, Deanna, Clarkin, Owen M., Towler, Mark R.

Volltext